ClinicalTrials.gg
RecruitingNCT06822907PREV-HOSPITUpdated Mar 30, 2026

Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults

A Phase 4 interventional study of Early intervention and Delayed intervention in Acute Febrile Illness and Pneumococcal Infections, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 24 sites in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,052
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Pneumococcal Infections with a site in France — 2 open to participants now, 2 under way, none of them phase 3. Pneumococcal Infections · France.

Planned enrollment
Largest of 16
1,052 · median 199
Started
2025
the only one that year
Phase 4
2 of 23
1 open now
Registered
23rd of 23
by date
Lead sponsor
2 of 23
Centre Hospitalier Universitaire de Saint Etienne

Among the 23 studies in Pneumococcal Infections with a site in France, this one has the largest planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 4, and was the 23rd registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 23 studies in Pneumococcal Infections with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Pneumococcal Infections with a site in France, or all of them as a file.
02

Study summary

Streptococcus pneumoniae is responsible for serious infections associated to numerous hospitalizations and high rate of mortality. The incidence and therefore the burden of pneumococcal infections have been significantly reduced thanks to the use of pneumococcal conjugate vaccines (PCVs). PCVs were shown to be effective against vaccine-type serotypes causing both non-invasive and invasive pneumococcal diseases (IPD) in children and adults. PCVs use in children was shown to have an impact on IPD incidence among adults due to herd immunity and on antimicrobial resistance. To increase the protection of at-risk patients against IPD, the 20-valent PCV (PCV-20) is recently recommended in adults, after a period where PCV-13 followed by pneumococcal polysaccharide vaccine 23 valent (PPV-23) was recommended. PCV-20 effectiveness against IPD and against pneumonia was inferred from immunobridging with PCV-13. Indeed PCV-13 was shown effective to reduce the incidence of low respiratory tract infections and IPD (bacteraemia and meningitis) in 65-years-old-adults and older. Currently immunization against S. pneumoniae is recommended with PCV-20 for adult patients at-risk for IPD such as immunocompromised (=high-risk patients) and in immunocompetent people with underlying chronic conditions (cardiovascular, liver, pulmonary, kidney diseases and diabetes mellitus) (=medium risk patients). However, vaccine coverage against IPD in adults remains low globally, and does not exceed 5 % in France. Reducing missed opportunities of vaccination for S. pneumoniae is crucial.

Read the detailed description

Patients at-risk of IPD are very frequently hospitalized for acute febrile illnesses. More than 50 % of the IPD at-risk patients hospitalized for an IPD or a pneumonia have been admitted to the hospital during the past 5 years without receiving a pneumococcal vaccination. Hospitalization appears to be therefore an opportunity to provide vaccines. However, physicians usually consider that vaccines should be postponed during an acute febrile illness including if non-severe. This consideration of not vaccinating during an acute febrile illness is however not evidence-based. This is associated to concerns about a potential risk of an impaired response to the vaccine and safety. In children, data about vaccination during a febrile illness have shown no safety nor efficacy concerns. In most countries, recommendations regarding this particular point are unclear.

In fine, vaccination is then rarely provided during the hospital stay as well as after discharge including in the USA, a country where it is recommended to vaccinate whatever the body temperature is and during hospitalization. Reluctance to immunize adults in this situation is probably due to the absence of evidence showing that it is as effective and safe as vaccinating patients without an acute or febrile illness.

To reduce the number of missed opportunities to immunize adults against S. pneumoniae, investigators aim to demonstrate that the administration of PCV-20 during an acute non-severe febrile illness is non-inferior than the administration one month after fever resolution in terms of immunogenicity (assessed by vaccine types (VT) Immunoglobulin G (IgG) concentrations and at least 2-fold change increase), and that it is as safe.

03

Conditions studied

  • Acute Febrile Illness
  • Pneumococcal Infections

Keywords

  • vaccin
  • pneumococcal
  • Prevenar 20
  • Acute febrile illness
  • infections
  • PCV-20
  • PCV-21
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of body temperature ≥ 38°C measured at least twice prior to randomization (Randomization must be performed as soon as possible on a febrile patient or 72 hours after apyrexia at the latest)
  • Having at least one comorbidity that defines patients as medium or high risk for pneumococcal invasive infection:

    • Medium risk: Cyanogenic congenital heart disease; chronic heart failure; chronic respiratory failure; ; emphysema; severe asthma under chronic treatment; chronic renal failure; chronic liver disease; diabetes mellitus treated; Osteo-meningeal leak or cochlear implant; Age > 65 years old.
    • High risk : Hypo or asplenic people; hereditary immunodeficiency syndromes; people living with ; solid organ transplanted; People under immunosuppressors (, biotherapy) for an auto-immune or an inflammatory chronic disease; patients with nephrotic syndrome
  • Hospitalization for > 24 hours long
  • Social security affiliation
  • Signed

Exclusion criteria

Exclusion criteria :

  • Patient unable to give
  • Curators, wardship
  • History of previous vaccination with PCV-7 or PCV-13 or PCV-20
  • History of PPV-23 in the previous year
  • Patient having received another vaccination within one month prior to inclusion or planning another vaccination in the month after inclusion except for Influenza vaccine.
  • Patient with history of bone marrow transplantation
  • Patient with haematological
  • Patient under chemotherapy for solid tumor or with a history of chemotherapy in the past three months
  • Patient treated with Rituximab currently or in the past 6 months
  • Patient with Sequential Organ Failure Assessment (qSOFA ) score ≥ 2 at randomization (acute severe febrile illness)
  • Patient hospitalized in an Intensive Care Unit
  • Pregnancy
  • Breastfeeding woman
  • Recipients of polyclonal gammaglobulins in the past three months
  • Inability to follow the protocol
  • Bleeding disorder contra-indicating intramuscular injection according to the investigator
  • History of allergy to PCV-20 or vaccine-related components.
  • S. pneumoniae infection with laboratory confirmation (blood culture, culture from a sterile site, urinary or Cerebrospinal fluid antigens, sputum culture with > 10\^7 colony forming unit (CFU)/mL) being the cause of the current hospitalization
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,052 participants (estimated)

Study arms

  • Experimental
    Early vaccination

    The patient will receive unique dose of the PCV-20 vaccine as soon as possible and until 72h after apyrexia. The "Prevenar 20" will be used

    Biological: Early intervention

  • Active comparator
    Delayed vaccination

    From 15 days and until 58 days after fever resolution (i.e after the first day with a body temperature \< 37.5°C without paracetamol use in the 6 previous hours) (whether or not the patient has been discharged) in the absence of fever, the patient will receive PCV-20 vaccination The "Prevenar 20" will be used

    Biological: Delayed intervention

Interventions

  • BiologicalEarly intervention

    In this arm, patient will receive unique dose of the PCV-20 vaccine (Prevnar 20) as soon as possible and until 72h after apyrexia. The "Prevenar 20" will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults.

  • BiologicalDelayed intervention

    In this arm, from 15 days and until 58 days after fever resolution (i.e after the first day with a body temperature \< 37.5°C without paracetamol use in the 6 previous hours) (whether or not the patient has been discharged) in the absence of fever, the patient will receive unique dose of the PCV-20 vaccine (Prevnar 20). The "Prevenar 20" will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults.

06

What researchers measure

Primary outcomes

  1. Proportion of immune "good responders" to PCV-20 in both arms

    Good responders is defined as - a seroconversion (a 2-fold increase in VT IgG after vaccination), for ≥10 vaccine serotypes (VT) among the 13 tested on 20 in ELISA, AND an immune protective response defined as ELISA IgG \> 1,3 μg/mL in ≥ 10 out 13 VT. OR \- -a seroconversion (a 4-fold increase in VT IgG after vaccination), for ≥10 vaccine serotypes (VT) among the 13 tested on 20 in ELISA, AND an immune protective response defined as ELISA IgG \< 1,3 μg/mL in ≥ 10 out 13 VT.

    Time frame: 1 month post vaccination

Secondary outcomes

  1. Safety endpoints in both arms in the month following vaccination : adverse events

    Number, type and severity of solicited (in the 7 days following vaccination) and unsolicited (in the month following vaccination) adverse events

    Time frame: 1 month post vaccination

  2. Frequency of local reactions

    Local reactions will be defined as : pain, redness, and swelling at the study vaccine injection site and limitation of arm movement

    Time frame: 1 month post vaccination

  3. Frequency of systemic events related to the vaccination

    Onset or worsening of fever, diarrhoea, chills, fatigue, headache, vomiting, decreased appetite, rash, muscle pain, joint pain). An independent blinded central adjudication committee will define the onset or worsening of symptoms and will review all systemic events.

    Time frame: 1 month post vaccination

  4. Proportion of immune good responders serotype by serotype

    "Good responders" being defined above (primary end-point) A blood sample for immunologic analysis will be performed

    Time frame: 1 month post vaccination

  5. opsonophagocytic activity (OPA) IgG titers for serotype by serotype

    A blood sample for immunologic analysis will be performed. ELISA method will be used for immunologic analysis.

    Time frame: 1 month post vaccination

  6. Proportion of the participants immune "good responders" to PCV-20 in both arms.

    "Good responders" being defined above (primary end-point) A blood sample for immunologic analysis will be performed. ELISA method will be used for immunologic analysis.

    Time frame: 1 year post vaccination

  7. Number of low respiratory tract infections events

    Data about occurrence of respiratory infections will be recorded.

    Time frame: 1 year post vaccination

  8. Number of confirmed S.pneumoniae infections

    Data about pneumococcal infection will be recorded.

    Time frame: 1 year post vaccination

  9. Analyze the gut microbiota on the immune response

    Analyze the gut microbiota on the immune response in both arm ( during an acute febrile illness or 15-58 days after resolution of the acute febrile illness) A stool sample is taken before vaccination

    Time frame: 1 year post vaccination

  10. Reactogenic inflammatory response after vaccination

    Fold change kinetics (transcriptomics) (before and at 24 hours after vaccination) of vaccine-induced gene signatures in peripheral blood mononuclear cells and serum cytokine levels at baseline and 24 hours after vaccination in both arms.

    Time frame: 1 month post vaccination

  11. Frequency of specific PCV-20 interferon-gamma (IFNg) secreting CD4 or CD8 T cells

    Blood sample will be collected 1 month post-vaccination.

    Time frame: 1 month post vaccination

  12. Frequency of specific PCV-20 IFNg secreting CD4 or CD8 T cells

    Blood sample will be collected 1 year post-vaccination.

    Time frame: 1 year post vaccination

  13. Proportion of volunteers with circulatory immunoglobulin A (IgA)

    Blood sample will be collected 1 month post-vaccination.

    Time frame: 1 month post vaccination

07

Study locations

1 of 24 sites recruiting
  • CHU de Saint-Etienne
    Saint-Etienne, France 42055, France
    Recruiting
    • Elisabeth BOTELHO-NEVERS, MD PhD · Principal investigator
  • Centre Hospitalier
    Annecy, 74000, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Besançon, 25000, France
    Not yet recruiting
  • Centre Hospitalier
    Bordeaux, 33000, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Brest, 29609, France
    Not yet recruiting
  • Centre Hospitalier
    Brest, 29609, France
    Not yet recruiting
  • Centre Hospitalier General Metropole Savoie
    Chambéry, 73011, France
    Not yet recruiting
  • Centre Hospitalier de Creteil
    Créteil, 94000, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Dijon, 21000, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Grenoble, 38043, France
    Not yet recruiting
  • Centre Hospitalier
    La Roche-sur-Yon, 85925, France
    Not yet recruiting
  • Centre Hospitalier General
    Le Mans, 72000, France
    Not yet recruiting
  • Centre Hospitalier
    Le Puy-en-Velay, 43000, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Lille, 59037, France
    Not yet recruiting
  • Hospices Civils de Lyon
    Lyon, 69004, France
    Not yet recruiting
  • Centre Hospitalier Regional Universitaire
    Montpellier, 34295, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Nancy, 54511, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Nantes, 44093, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Nice, 06202, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Nîmes, 30029, France
    Not yet recruiting
  • Centre Hospitalier Bichat
    Paris, 75012, France
    Not yet recruiting
  • Assistance Publique Hopitaux de Paris
    Paris, 75679, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Rennes, 35000, France
    Not yet recruiting
  • Centre Hospitalier Universitaire
    Rouen, 76000, France
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2028, 33 months after the start.

Of 21 phase 4 interventional studies under Pneumococcal Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's planned 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 12, 2025
StartActual
Dec 17, 2025
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2028
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06822907
Collaborators
Ministry of Health, France, IREIVAC/COVIREIVAC Network
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Dec 17, 2025
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Mar 30, 2026

Study contacts

Elisabeth BOTELHO-NEVERS, MD PhD
Contact
Elisabeth.Botelho-Nevers@chu-st-etienne.fr
(0)477829234 ext. +33
Elisabeth BOTELHO-NEVERS, MD PhD
principal investigator · Centre Hospitalier Universitaire de Saint Etienne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion